FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056656886> ?p ?o ?g. }

• W2056656886 endingPage "307" @default.
• W2056656886 startingPage "307" @default.
• W2056656886 abstract "Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration? Nicola G Ghazi, Tyler Q Kirk, Robert M Knape, James S Tiedeman, Brian P ConwayDepartment of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USAPurpose: To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy.Methods: Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of follow up. Outcome measures were best corrected visual acuity (BCVA) and optical coherence tomography (OCT) central macular thickness. Injections were repeated if no further improvement was observed.Results: Twenty-nine eyes of 29 patients were included. The average BCVA improved from 20/148 at baseline to 20/106 at twelve weeks (P = 0.041). Of the 29 eyes, 25 (86.2%) had stable or improved BCVA. Average mean central macular thickness measured by OCT improved from 351 μm at baseline to 278 μm at 12 weeks (P = 0.003). Stabilization of vision and improved OCT central macular thickness were maintained for at least eight weeks following only a single injection in the majority of eyes. During the three months of follow up, only five eyes (17.2%) required repeat injections, with only three (10.3%) requiring retreatment at eight weeks and none at four weeks. No significant ocular or systemic side effects were observed. Conclusion: This short-term data suggests that bevacizumab appears to be a safe and effective treatment for neovascular AMD. Injections as frequent as every month do not appear to be necessary since initial treatment effect appears to be maintained for at least eight weeks in almost all of our patients.Keywords: retina, Avastin®, bevacizumab, neovascular age-related macular degeneration, AMD" @default.
• W2056656886 created "2016-06-24" @default.
• W2056656886 creator A5056766552 @default.
• W2056656886 date "2010-04-01" @default.
• W2056656886 modified "2023-09-30" @default.
• W2056656886 title "Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?" @default.
• W2056656886 cites W1513613431 @default.
• W2056656886 cites W1965259073 @default.
• W2056656886 cites W1968609549 @default.
• W2056656886 cites W1988233478 @default.
• W2056656886 cites W1992257311 @default.
• W2056656886 cites W1995708259 @default.
• W2056656886 cites W2015843817 @default.
• W2056656886 cites W2023523208 @default.
• W2056656886 cites W2026626516 @default.
• W2056656886 cites W2033245558 @default.
• W2056656886 cites W2039446733 @default.
• W2056656886 cites W2058775052 @default.
• W2056656886 cites W2085366579 @default.
• W2056656886 cites W2096735172 @default.
• W2056656886 cites W2114615391 @default.
• W2056656886 cites W2155905635 @default.
• W2056656886 cites W2157769714 @default.
• W2056656886 cites W2262759767 @default.
• W2056656886 doi "https://doi.org/10.2147/opth.s8598" @default.
• W2056656886 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2861937" @default.
• W2056656886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20463798" @default.
• W2056656886 hasPublicationYear "2010" @default.
• W2056656886 type Work @default.
• W2056656886 sameAs 2056656886 @default.
• W2056656886 citedByCount "9" @default.
• W2056656886 countsByYear W20566568862013 @default.
• W2056656886 countsByYear W20566568862014 @default.
• W2056656886 countsByYear W20566568862016 @default.
• W2056656886 countsByYear W20566568862023 @default.
• W2056656886 crossrefType "journal-article" @default.
• W2056656886 hasAuthorship W2056656886A5056766552 @default.
• W2056656886 hasBestOaLocation W20566568861 @default.
• W2056656886 hasConcept C118487528 @default.
• W2056656886 hasConcept C141071460 @default.
• W2056656886 hasConcept C2776403814 @default.
• W2056656886 hasConcept C2776694085 @default.
• W2056656886 hasConcept C2777802072 @default.
• W2056656886 hasConcept C2778257484 @default.
• W2056656886 hasConcept C71924100 @default.
• W2056656886 hasConceptScore W2056656886C118487528 @default.
• W2056656886 hasConceptScore W2056656886C141071460 @default.
• W2056656886 hasConceptScore W2056656886C2776403814 @default.
• W2056656886 hasConceptScore W2056656886C2776694085 @default.
• W2056656886 hasConceptScore W2056656886C2777802072 @default.
• W2056656886 hasConceptScore W2056656886C2778257484 @default.
• W2056656886 hasConceptScore W2056656886C71924100 @default.
• W2056656886 hasLocation W20566568861 @default.
• W2056656886 hasLocation W20566568862 @default.
• W2056656886 hasLocation W20566568863 @default.
• W2056656886 hasLocation W20566568864 @default.
• W2056656886 hasOpenAccess W2056656886 @default.
• W2056656886 hasPrimaryLocation W20566568861 @default.
• W2056656886 hasRelatedWork W1195529740 @default.
• W2056656886 hasRelatedWork W1530737772 @default.
• W2056656886 hasRelatedWork W1988039871 @default.
• W2056656886 hasRelatedWork W1993747607 @default.
• W2056656886 hasRelatedWork W1995044506 @default.
• W2056656886 hasRelatedWork W2034093159 @default.
• W2056656886 hasRelatedWork W2042956061 @default.
• W2056656886 hasRelatedWork W2314067402 @default.
• W2056656886 hasRelatedWork W2553987180 @default.
• W2056656886 hasRelatedWork W2599281049 @default.
• W2056656886 isParatext "false" @default.
• W2056656886 isRetracted "false" @default.
• W2056656886 magId "2056656886" @default.
• W2056656886 workType "article" @default.